Panobinostat (LBH589)

Name: Panobinostat (LBH589)
Brand: Selleck Chemicals
SKU: S1030
Rating: 5 (227 reviews)

For research use only.

Catalog No.S1030 Synonyms: NVP-LBH589

227 publications

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Selleck's Panobinostat (LBH589) has been cited by 227 publications

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 36(5):528-544

PubMed: 31631026 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):782-797

PubMed: 31085178 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Nat Genet, 2018, 50(10):1442-1451

PubMed: 30224647 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cell, 2014, 159(5):1110-25

PubMed: 25416949 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Commun, 2020, 11(1):583

PubMed: 31996670 ( click the link to review the publication )

PLoS Pathog, 2020, 16(3):e1008442

PubMed: 32196533 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32059481 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )

Sci Rep, 2020, 10(1):3470

PubMed: 32103105 ( click the link to review the publication )

Exp Hematol, 2020, 81:32-41

PubMed: 31954171 ( click the link to review the publication )
Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04021-y

PubMed: 31894347 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Cell Res, 2019, 29(4):286-304

PubMed: 30631154 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3319

PubMed: 31346162 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz215

PubMed: 31711240 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cell Rep, 2019, 29(9):2783-2795

PubMed: 31775045 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):185

PubMed: 31053152 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007991

PubMed: 31425551 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):134

PubMed: 31801577 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )
Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1666-1676

PubMed: 30954557 ( click the link to review the publication )

J Biomed Nanotechnol, 2019, 15(5):979-992

PubMed: 30890229 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Biomolecules, 2019, 9(5)

PubMed: 31083537 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18970-18984

PubMed: 30916359 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(2)

PubMed: 30455231 ( click the link to review the publication )

Epigenetics Chromatin, 2019, 12(1):18

PubMed: 30871586 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Mol Carcinog, 2019, 58(12):2230-2240

PubMed: 31478563 ( click the link to review the publication )

Mol Carcinog, 2019, 58(2):234-246

PubMed: 30303565 ( click the link to review the publication )

Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

Mol Genet Genomic Med, 2019, 7(5):e613

PubMed: 30891950 ( click the link to review the publication )

Childs Nerv Syst, 2019, 35(5):823-831

PubMed: 30815722 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

J Virus Erad, 2019, 5(3):133-137

PubMed: 31700655 ( click the link to review the publication )
Nat Commun, 2018, 9(1):4866

PubMed: 30451831 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129.

PubMed: 29066507 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Oncogene, 2018, 37(6):722-731

PubMed: 29059175 ( click the link to review the publication )

Cancer Lett, 2018, 417:152-160

PubMed: 29306016 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1705-1716

PubMed: 29748211 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(2):201-212

PubMed: 29260509 ( click the link to review the publication )

J Immunol, 2018, 201(3):1086-1096

PubMed: 29914885 ( click the link to review the publication )

J Virol, 2018, 92(13)

PubMed: 29643247 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9472

PubMed: 29930256 ( click the link to review the publication )

Biomed Pharmacother, 2018, 100:509-520

PubMed: 29494986 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

J Ethnopharmacol, 2018, 211:267-277

PubMed: 28970153 ( click the link to review the publication )

Exp Cell Res, 2018, 363(2):196-207

PubMed: 29317217 ( click the link to review the publication )
PLoS One, 2018, 13(12):e0208147

PubMed: 30592723 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(1):61-74

PubMed: 29049036 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36530-36541

PubMed: 30559935 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28586-28598

PubMed: 29983882 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 100(1):174-187

PubMed: 29107335 ( click the link to review the publication )

Nat Commun, 2017, 8(1):728

PubMed: 28959017 ( click the link to review the publication )

Cancer Res, 2017, 77(11):3027-3039

PubMed: 28363998 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Arch Toxicol, 2017, 91(1):365-391

PubMed: 27015953 ( click the link to review the publication )

Arch Toxicol, 2017, 91(2):839-864

PubMed: 27188386 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Br J Haematol, 2017, 178(5):728-738

PubMed: 28480959 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Int J Nanomedicine, 2017, 12:1385-1399

PubMed: 28260886 ( click the link to review the publication )

J Biol Chem, 2017, 292(9):3683-3691

PubMed: 28087699 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Exp Cell Res, 2017, 350(1):218-225

PubMed: 27914787 ( click the link to review the publication )
Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169485

PubMed: 28052119 ( click the link to review the publication )

Horm Cancer, 2017, 8(4):257-267

PubMed: 28516379 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1575-1583

PubMed: 29296798 ( click the link to review the publication )

Genom Data, 2017, 12:14-16

PubMed: 28239551 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )

Oncotarget, 2017, 8(18):30019-30029

PubMed: 28415789 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56747-56757

PubMed: 28915627 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94569-94579

PubMed: 29212250 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:127-148

PubMed: 27761818 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2534-44

PubMed: 26733615 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Oncogene, 2016, 35(46):6026-6037

PubMed: 27157610 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2016, 3:16003

PubMed: 27626039 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )
Sci Rep, 2016, 6:30749

PubMed: 27480951 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:1393-1405

PubMed: 27802904 ( click the link to review the publication )

Retrovirology, 2016, 13(1):36

PubMed: 27206407 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Am J Transl Res, 2016, 8(9):3893-3902

PubMed: 27725868 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0148912

PubMed: 26859414 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

J Org Chem, 2016, 81(22):11324-11334

PubMed: 27768313 ( click the link to review the publication )

JCI Insight, 2016, 1(5):e85061

PubMed: 27699258 ( click the link to review the publication )

Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206258

PubMed: 25589513 ( click the link to review the publication )

Biomaterials, 2015, 73:110-9

PubMed: 26406451 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Arch Toxicol, 2015, 89(9):1599-618

PubMed: 26272509 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

Mol Pharm, 2015, 12(7):2469-76

PubMed: 26030093 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074.jbc.M114.624361

PubMed: 25737447 ( click the link to review the publication )
J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(12):1784-93

PubMed: 26529495 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0126566

PubMed: 26176219 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134426

PubMed: 26247786 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Exp Hematol, 2015, 43(6):448-61

PubMed: 25704054 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2088-100

PubMed: 25576920 ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Anal Chem, 2014, 86(10):4642-7

PubMed: 24559101 ( click the link to review the publication )

Br J Cancer, 2014, 111(2):281-91

PubMed: 24946002 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Immunol, 2014, 193(3):1333-43

PubMed: 24973453 ( click the link to review the publication )

Mol Carcinog, 2014, 53(9):722-35

PubMed: 23475695 ( click the link to review the publication )

BMC Cancer, 2014, 14:17

PubMed: 24418474 ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )
PLoS One, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):649-54

PubMed: 25193706 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Leukemia, 2013, 27(6):1291-300

PubMed: 23411464 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):17-26

PubMed: 22995071 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R58

PubMed: 23879992 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):429-33

PubMed: 23932191 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1507-14

PubMed: 23824064 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1325-34

PubMed: 23515752 ( click the link to review the publication )

PLoS One, 2013, 8(8):e74253

PubMed: 23991216 ( click the link to review the publication )

PLoS One, 2013, 8(11):e79106

PubMed: 24244429 ( click the link to review the publication )

PLoS One, 2013, 8(9):e76662

PubMed: 24098799 ( click the link to review the publication )

PLoS One, 2013, 8(7):e69992

PubMed: 23922886 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Theriogenology, 2013, 80(6):630-5

PubMed: 23866857 ( click the link to review the publication )

Protein Expr Purif, 2013, 92(1):119-127

PubMed: 24056254 ( click the link to review the publication )

Genet Mol Res, 2013, 12(4):5405-13

PubMed: 24301913 ( click the link to review the publication )
The University of Western Ontario, 2013, CHAE YOUNG HAN

PubMed: ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Blood, 2012, 119(6):1450-8

PubMed: 22144178 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

J Neurooncol, 2012, 110(3):335-48

PubMed: 23054560 ( click the link to review the publication )

Acta Neuropathol, 2011, 122(5):637-50

PubMed: 21863243 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 391(4):1748-51

PubMed: 20043870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Targets

HDAC (MOLT-4 cells) ^[1]	HDAC (Reh cells) ^[1]
5 nM	20 nM

In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. ^[1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT29	NVXjSWZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLvVGoxNTFyIN88US=>	NEnOcGoxNTRiZB?=		NGXWSXVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MnHrNlY4ODJ5OES=
HepG2	NWXC[41sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLhfZExNTFyIN88US=>	M2HXUFAuPCCm		MmPybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MVWyOlcxOjd6NB?=
HT29	MXLGeY5kfGmxbjDBd5NigQ>?	MkXEOVDDqG6P	MY[yOE04OiCq		MWrpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G\|cHHz[UA{KGGodHXyJFQ5yqCqwrC=	M2XxfFI3PzB{N{i0
HepG2	NVSwTXoyTnWwY4Tpc44hSXO\|YYm=	NGHNb3Y2OMLibl2=	M37YfVI1NTd{IHi=		M{HU[olv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhOjUEoHlCpC=>	NEP6XGgzPjdyMke4OC=>
HCC827	MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DLUFUwPy53L{GwJI5O	MWC3NuKhcA>?	NFTVUXFFVVOR	Mljv[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ?	MV6yOlY4PTR6NB?=
A549	MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoHCNVAwOTVxMkCgcm0>	MofuO\|LDqGh?	MkD1SG1UVw>?	NGLx[HBmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?=	MoLPNlY3PzV2OES=
NCI-H460	NYK1NohwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEO3NVMyOC9{MD:zNEBvVQ>?	NHL3W\|Y4OsLiaB?=	NEjjeGlFVVOR	Mort[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ?	NV\6N4Y5OjZ4N{W0PFQ>
J89GFP	NXLDe3FkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4[2fGROW00EoB?=	MlHTSWM2OD12OT64OUDDuSBzMj62OUBvVQ>?	NWj3c2pHOjZ3NkO1Olg>
THP89GFP	NGraNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml3CSG1UV8Li	NWT6fnp1TUN3ME2xPU4{PCEEsTC2MlQ{KG6P	MYSyOlU3OzV4OB?=
SK-NEP-1	MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYCwMlAy6oDVMUCuNEDPxE1?	MWWyOEBp	M3nMXGROW00EoB?=	NIjEUYdKSzVyPUe2MlM1KG6P	MoXmNlYyPzZ{MUm=
G401	M32wdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVSwMlAy6oDVMUCuNEDPxE1?	M{fNUVI1KGh?	NWjYSYZqTE2VT9Mg	MljwTWM2OD1zNEOuNFIhdk1?	NX\sb5hHOjZzN{[yNVk>
SK-NEP-1	NIX5c4ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NGT1UYo2OCCwTR?=	NULwPIpJOeLCk{Sg[C=>	M3nFc2ROW00EoB?=	M{TYOpJm\HWlZYOgZ4VtdCC\|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>?	NVnXPGVKOjZzN{[yNVk>
G401	NYfZNFZOS2WubDDWbYFjcWyrdImgRZN{[Xl?	MV[1NEBvVQ>?	NYe1dnNzOeLCk{Sg[C=>	MXzEUXNQyqB?	M3u4bZJm\HWlZYOgZ4VtdCC\|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>?	MlzoNlYyPzZ{MUm=
SK-NEP-1	NIPVSmNCeG:ydH;zbZMhSXO\|YYm=	NInjTpg2OC9zMECgcm0>	M33PZlI1KGh?	NEjib4dFVVORwrC=	NV70SHJNcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NF\QfYwzPjF5NkKxPS=>
G401	NXHtTlJmSXCxcITvd4l{KEG\|c3H5	MX[1NE8yODBibl2=	MlvGNlQhcA>?	NG\OZZpFVVORwrC=	M3vUSolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MYqyOlE4PjJzOR?=
SK-NEP-1	MlX4SpVv[3Srb36gRZN{[Xl?	NFjRRWQ2OC9zMECgcm0>	NW\QNo17OjRiaB?=	NW[4T2s{TE2VT9Mg	MnX0d4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>?	MknENlYyPzZ{MUm=
G401	MmnYSpVv[3Srb36gRZN{[Xl?	NHX2UJU2OC9zMECgcm0>	MV:yOEBp	MVTEUXNQyqB?	NVz5ZmdGe2ixd4OgeIhmKGmwZIXjeIlwdiCxZjDEUmEh\nKjZ33lcpRifGmxbh?=	M13HXlI3OTd4MkG5
SK-NEP-1	NHzUT2hHfW6ldHnvckBCe3OjeR?=	M332dlUxNzFyMDDuUS=>	M1HvXVI1KGh?	M3LSWGROW00EoB?=	NW\DSIxFcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB?	NYf0NYJrOjZzN{[yNVk>
G401	M1rkNGZ2dmO2aX;uJGF{e2G7	NI\NcYI2OC9zMECgcm0>	NHize\|AzPCCq	MYrEUXNQyqB?	NXTnfZVqcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB?	M3K5SFI3OTd4MkG5
RPMI 8226	M{m0WWNmdGxiU4Xyeol3[WxiQYPzZZk>	NVvLS4tYOi92L{[gcm0>	NVOxTlVFPDkkgJno		NFH4NmtqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq	NUPzSZNCOjZyMECyPVI>
OPM2	MlrER4VtdCCVdYL2bZZidCCDc4PhfS=>	NVfWN3E{Oi92L{[gcm0>	NIrtTmQ1QOLCiXi=		MXfpcoR2[2W\|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp	M4fIRlI3ODByMkmy
U266	M{HINWNmdGxiU4Xyeol3[WxiQYPzZZk>	MnTLNk81NzZibl2=	NILaTII1QOLCiXi=		M4r0bIlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh?	MWCyOlAxODJ7Mh?=
H929	NIHjeGVE\WyuIGP1dpZqfmGuIFHzd4F6	M3rvfVIwPC94IH7N	NWniUo04PDkkgJno		NVnvR2FscW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?=	MlH0NlYxODB{OUK=
RPMI 8226	NFjm[olCeG:ydH;zbZMhSXO\|YYm=	MUe05qCKdk1?	NV\p[Gt[OjRxNEigbC=>		NXG1WWZWcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	NVvuSplSOjZyMECyPVI>
HCC827	NVTBcFk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGOxPZkyOCCwTR?=	Mn7aOFghcA>?	NHeycXRFVVOR	MUTlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>?	NIHtS5YzPTl2NE[xOy=>
NCI-H23	MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPyb3YyOCCwTR?=	MnXiOFghcA>?	MVvEUXNQ	NXPRdG5H\W6qYX7j[ZMh[2m\|cHzheIlvKHOnboPpeIl3cXS7wrC=	MX2yOVk1PDZzNx?=
AML3	M3X6UGZ2dmO2aX;uJGF{e2G7	MknLNE0yKM7:TR?=	MnLTNlTDqGh?		M3TxdYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M3;HPFI2PjF{OUSx
ML-1	MljXSpVv[3Srb36gRZN{[Xl?	MnTaNE0yKM7:TR?=	MWOyOOKhcA>?		MonjbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXn3SI9rOjV4MUK5OFE>
RPMI-8226vr10	MnTDSpVv[3Srb36gRZN{[Xl?	Ml7yNE0yKM7:TR?=	M1LVeVI1yqCq		MWHpcoR2[2W\|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NHzEWZkzPTZzMkm0NS=>
ML-1	NEHpPYdHfW6ldHnvckBCe3OjeR?=	NWPBendXOSEQvF2=	MUWyOOKhcA>?		NVjkcI1ZcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ>	NGrWd2YzPTZzMkm0NS=>
RPMI-8226vr10	NUjtVZN4TnWwY4Tpc44hSXO\|YYm=	MWWxJO69VQ>?	MlPFNlTDqGh?		NGDKVIhqdmO{ZXHz[ZMh[2G\|cHHz[U0{KGGldHn2bZR6KDJwNT3mc4xl	NVnjRZRGOjV4MUK5OFE>
SK-N-BE (2)	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEjPXZUzPOLCiXi=		MlXHTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P	NFjsOmMzPTNyOEmxOi=>
SK-N-BE (2), PAN MK	NFTyd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3rGdFI16oDLaB?=		M4\3UmlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?=	MknVNlU{ODh7MU[=
SK-N-BE (2), MK PAN	MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV7sWHBFOjUkgJno		MUfJR\|UxRTN6Mj6w5qCKyrIkgJm0N{4zKG6P	NUntOmsxOjV\|MEi5NVY>
SK-N-AS	NH21XXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFrlOWszPOLCiXi=		M3vJdGlEPTB;M{euNgKBkcLz4pEJNk41KG6P	MWiyOVMxQDlzNh?=
SK-N-DZ	NX;4[GRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVSyOQKBkWh?		NIiyVoVKSzVyPUG3MlHjiIoEsfMAjVAvPCCwTR?=	M3TvbVI2OzB6OUG2
Caki-1	M3;BWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIr5OVEyOC9{NT:1NEBvVQ>?	Ml\qOFghcA>?		MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ?	M{[xSVI2Ojd7MUmx
ACHN	NInYT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzhNVAwOjVxNUCgcm0>	MXW0PEBp		M4Dhe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?=	NHfkbJMzPTJ5OUG5NS=>
769-P	NV;SW3RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLQNVAwOjVxNUCgcm0>	NX61bpB{PDhiaB?=		MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ?	MV[yOVI4QTF7MR?=
786-O	MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfLfI84OTBxMkWvOVAhdk1?	MnLBOFghcA>?		NI[ybXNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	NEfH[GgzPTJ5OUG5NS=>
Caki-1	MoLCRZBweHSxc3nzJGF{e2G7	M{TvR\|UxKG6P	MleyOFghcA>?		NU\iVodncW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK=	MVeyOVI4QTF7MR?=
ACHN	NYnYVlg5SXCxcITvd4l{KEG\|c3H5	NGLCOXE2OCCwTR?=	NGD3O4E1QCCq		NH3FOHVqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	NEDNNpUzPTJ5OUG5NS=>
769-P	MlnnRZBweHSxc3nzJGF{e2G7	NFPoSIs2OCCwTR?=	NYTaPGdLPDhiaB?=		NF74fJVqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	M{fTVVI2Ojd7MUmx
786-O	MnHvRZBweHSxc3nzJGF{e2G7	M2TFS\|UxKG6P	NUfKNHVZPDhiaB?=		MlnhbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ?	NYXJc5FROjV{N{mxPVE>
Caki-1	NUH6eohCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYiyOU82OCCwTR?=	NX70[3lqPDhiaB?=	NHfiTI5FVVOR	MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk	NF[yfGUzPTF5NkO1OC=>
ACHN	MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPydodEOjVxNUCgcm0>	M3vxUlQ5KGh?	MkniSG1UVw>?	NWD4VJVwcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigZo9zfGW8b33pZi=>	MVqyOVE4PjN3NB?=
769-P	NUT5dWFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX6xc\|FnOjVxNUCgcm0>	M4HidlQ5KGh?	NXPlcpY5TE2VTx?=	MV7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk	MXWyOVE4PjN3NB?=
Caki-1	NHHmToVEd2yxbomgSo9zdWG2aX;uJGF{e2G7	NGrXdYY2OCCwTR?=	MXK3MVE1KGR?	NXXDNWJiTE2VTx?=	M{PNcpN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh	MnXBNlUyPzZ\|NUS=
ACHN	NEXDOWhEd2yxbomgSo9zdWG2aX;uJGF{e2G7	MYi1NEBvVQ>?	NG\kUZA4NTF2IHS=	NWDKXnI6TE2VTx?=	NYnxW5BZe3WycILld5Nm\CClb3zvcpkh\m:{bXH0bY9vKHOrZ37p[olk[W62bImgZ49u[mmwZXSge4l1cCC5aYToJIJwenSnen;tbYIhyqB?	MViyOVE4PjN3NB?=
769-P	MVzDc4xwdnliRn;ycYF1cW:wIFHzd4F6	NHWxcJo2OCCwTR?=	NHH4WZY4NTF2IHS=	NXe1cm5QTE2VTx?=	M{jRPZN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh	NEDUcVAzPTF5NkO1OC=>
Caki-1	NIDrTJdCeG:ydH;zbZMhSXO\|YYm=	NWfHO\|lSPTBibl2=	NGLjeIY1QCCq	NXTWXnJuTE2VTx?=	NH\tfVlqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MkOxNlUyPzZ\|NUS=
ACHN	NVjLbGZZSXCxcITvd4l{KEG\|c3H5	NFnhTXE2OCCwTR?=	MmH2OFghcA>?	MYrEUXNQ	NH\0Oo9qdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MoTTNlUyPzZ\|NUS=
769-P	NUXVR5BDSXCxcITvd4l{KEG\|c3H5	M3LJNVUxKG6P	MlvmOFghcA>?	M3zKcGROW09?	NF25fohqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MUeyOVE4PjN3NB?=
MDA-MB-231	MV;Nc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk>	Mof3NVDDqG6P	NHGxd3g{yqCm	NHWxe3JFVVOR	MVHhcJRmenNiY3XscEBud3KyaH;sc4d6yqB?	MX2yOFgyODR7Nx?=
BT-549	MontUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6	NXXiUlBWOTEEoH7N	NWHHSYt5O8LiZB?=	MmnvSG1UVw>?	MlrwZYx1\XK\|IHPlcIwhdW:{cHjvcI9ogcLi	NX;y[HNLOjR6MUC0PVc>
MCF-7	M4PhVW1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>?	Mli4NVDDqG6P	Ml3rN:Kh\A>?	MnG1SG1UVw>?	NUH2fVdZ[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg	MYOyOFgyODR7Nx?=
MCF-7	M1rpfWZ2dmO2aX;uJGF{e2G7	M2TnNlUuPTBibl2=	M3qzfFI1KGh?	NIDmWGNFVVOR	MXny[YR2[2WmIITo[UBt\X[nbDDv[kBmgHC{ZYPzbY9vKG:oIFXS{tEtKFCUIHHu[EBHd3iDMdMg	M2TOXFI1OzZ4NEC3
CTS	Ml7RRZBweHSxc3nzJGF{e2G7	Mon4NQKBmzRyIH7NxsA>	NIDTenU1QCCq		MonXbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MkjUNlQzPDR2Mkm=
OCI-AML3	MYLBdI9xfG:\|aYOgRZN{[Xl?	MYGw5qCUPDBibl5CpC=>	M{LsPFQ5KGh?		NWfNd3ZycW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	Mlj4NlQzPDR2Mkm=
U937	MV7BdI9xfG:\|aYOgRZN{[Xl?	M163SlDjiJN2MDDuUeKh	M1XHNVQ5KGh?		NIDKdGpqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NXW0cJVtOjR{NES0Nlk>
PC3	MlLtRZBweHSxc3nzJGF{e2G7	NETjToUxNTFyMDDuUS=>	M4DENlI1NzR6IHi=		NVLxOmJQcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MYGyOFE3OzJ\|MB?=
PC3-AR	NInFSZBCeG:ydH;zbZMhSXO\|YYm=	M2TLW\|AuOTByIH7N	M4XDflI1NzR6IHi=		M{XPOYlv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NWP2c4NEOjRzNkOyN\|A>
PC3	NUTtb5JqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TSfFAuOTByIH7N	MUGyOE81QCCq		M3vFUolv\HWlZYOgZYNkfW23bHH0bY9vKG:oIIP1ZmcyKHCxcIXsZZRqd25?	NVy4S25[OjRzNkOyN\|A>
PC3-AR	NYK1b2FzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MViwMVExOCCwTR?=	MmLLNlQwPDhiaB?=		NHnx[IRqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKHSqZTDHNm0heGijc3W=	NUjuXYFJOjRzNkOyN\|A>
PC3	NEn2[2VHfW6ldHnvckBCe3OjeR?=	MXiwMVExOCCwTR?=	NY\hd4pCOjRiaB?=		Ml6xd5VxeHKnc4Pld{BmgHC{ZYPzbY9vKG:oIHHjeIl3[XSnZDDBWG0tKEGtdDDhcoQhTXKtMT:yJJBzd3SnaX6=	MV[yOFE3OzJ\|MB?=
PC3-AR	NHroW45HfW6ldHnvckBCe3OjeR?=	Mn\0NE0yODBibl2=	NIPBbVYzPCCq		M375c5N2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjDhZ5RqfmG2ZXSgRXRONCCDa4SgZY5lKEW{a{GvNkBxem:2ZXnu	NHPkeJAzPDF4M{KzNC=>
OS-RC-2	NGT3OGpE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVHlS4UxOC1zMECwJI5O	NFj0TXgzPC92OD:3NkBp	M{flNmROW09?	NHfDd3Bl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz	M1HKe\|I1OTR2N{O3
OS-RC-2	M{fCS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWe1NEBvVQ>?	Mnr4OFghcA>?	MW\EUXNQ	MkHRbY5lfWOnczDHNk9OKGG{cnXzeC=>	NY\4b\|hbOjRzNES3N\|c>
OS-RC-2	NI[5SWNCeG:ydH;zbZMhSXO\|YYm=	M332VlUxKG6P	NFX4R\|U1QCCq	M1XxdmROW09?	MVTpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	M2j1NFI1OTR2N{O3
SK-N-AS	M2C1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3j6cVDjiJN6MDDuUS=>	NWrBdIZ4PDhiaB?=		MV3JR\|UxRTJ5LkSgcm0>	MkfjNlQxQTh5OUm=
SK-N-DZ	NWHsXJExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NImzS4Ux6oDVOECgcm0>	MXW0PEBp		MlPQTWM2OD1{MT65JI5O	NVPRfopTOjRyOUi3PVk>
SK-N-SH	NXz6TGdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTEbFhbOOLCk{iwJI5O	MkS2OFghcA>?		MX\JR\|UxRTd{LkOgcm0>	M1r0R\|I1ODl6N{m5
SK-N-BE	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLiVVJ[OOLCk{iwJI5O	NGHi[nk1QCCq		NIT3eIxKSzVyPUe1MlQhdk1?	MWOyOFA6QDd7OR?=
SK-N-AS	MoXERZBweHSxc3nzJGF{e2G7	MXyw5qCUQDBibl2=	NFP3[ZI1QCCq		Mki4dI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	NVLjSHZWOjRyOUi3PVk>
SK-N-DZ	MkXFRZBweHSxc3nzJGF{e2G7	NIfZUHox6oDVOECgcm0>	MlXaOFghcA>?		NYnvSWN4eG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v	NVHLeWJsOjRyOUi3PVk>
SK-N-SH	NVWzW4lMSXCxcITvd4l{KEG\|c3H5	NF3PfoUx6oDVNECgcm0>	NHLYOFE1QCCq		M4T1dpBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	Ml73NlQxQTh5OUm=
SK-N-BE	M2jzSGFxd3C2b4Ppd{BCe3OjeR?=	NHv6PI0x6oDVNECgcm0>	MX:0PEBp		M4jqb5BwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	NEnLfZEzPDB7OEe5PS=>
SK-N-AS	M2PGdWZ2dmO2aX;uJGF{e2G7	NYDl[5F1OOLCk{iwJI5O	MlHROFghcA>?		NWS2S3p1cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>?	NVPwdlFFOjRyOUi3PVk>
SK-N-DZ	Mo\FSpVv[3Srb36gRZN{[Xl?	NFPSUZIx6oDVOECgcm0>	NEjSVYw1QCCq		NFLFSHVqdmS3Y3XzJIEh\G:\|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[UA{KGGwZDDQRXJR	MYSyOFA6QDd7OR?=
SK-N-SH	MVfGeY5kfGmxbjDBd5NigQ>?	NEjPfIIx6oDVNECgcm0>	NGnFNWs1QCCq		NEnlXXdqdmS3Y3XzJIEh\G:\|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[UA{KGGwZDDQRXJR	MViyOFA6QDd7OR?=
SK-N-BE	NIrRUG5HfW6ldHnvckBCe3OjeR?=	NWPqPIhZOOLCk{SwJI5O	NYHEPZRjPDhiaB?=		MnvsbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=>	MXKyOFA6QDd7OR?=
HCC-LM3	NHuybpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWGxMVExODBibl2=	MnnvNlQwPDhxN{KgbC=>	MY\EUXNQ	MWnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MW[yOFA6Ozl3Nh?=
HepG2	M1;OR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWCxMVExODBibl2=	NGjzOG0zPC92OD:3NkBp	NX;De5FFTE2VTx?=	NET1RZlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MlnRNlQxQTN7NU[=
SMMC-7721	NH3lS\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7WNU0yODByIH7N	M2npfFI1NzR6L{eyJIg>	M3;lemROW09?	MmDsbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NEjhSI8zPDB7M{m1Oi=>
HCC-LM3	MXLBdI9xfG:\|aYOgRZN{[Xl?	NULXVY9OPTBibl2=	MX20PEBp	MVrEUXNQ	MlvabY5lfWOnczDj[YxtKGGyb4D0c5NqeyC\|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk>	NFHoSnYzPDB7M{m1Oi=>
HepG2	NYLKfoZDSXCxcITvd4l{KEG\|c3H5	MmL5OVAhdk1?	M36xRVQ5KGh?	Ml;OSG1UVw>?	NF:5PYZqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMhOyxiODDhcoQhQQ>?	MYmyOFA6Ozl3Nh?=
SMMC-7721	MVTBdI9xfG:\|aYOgRZN{[Xl?	M2\SeFUxKG6P	MorlOFghcA>?	MUDEUXNQ	NX7rU21wcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG\|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl?	MVmyOFA6Ozl3Nh?=
HCC-LM3	M2jNPGZ2dmO2aX;uJGF{e2G7	NVi2SllLPTBxMUCwJI5O	MoDiNlQhcA>?	NV\mcWw2TE2VTx?=	M1XXSoRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC=	NFzIR2wzPDB7M{m1Oi=>
HepG2	NI\LRWxHfW6ldHnvckBCe3OjeR?=	M{fFbVUxNzFyMDDuUS=>	NYX4eItKOjRiaB?=	MknwSG1UVw>?	NX\KPVR[\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=>	NXH4dIhLOjRyOUO5OVY>
SMMC-7721	NVvGUXBRTnWwY4Tpc44hSXO\|YYm=	NEf5OXU2OC9zMECgcm0>	MVKyOEBp	NXu3eJpMTE2VTx?=	NYjRdZI1\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=>	M3;hU\|I1ODl\|OUW2
HCC-LM3	M3Hjd2Z2dmO2aX;uJGF{e2G7	NHfFcXg2OC9zMECgcm0>	M1\0[lI1KGh?	NICwcnVFVVOR	MUPkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v	NFv0ZZUzPDB7M{m1Oi=>
HepG2	M17ISGZ2dmO2aX;uJGF{e2G7	NFXjcHA2OC9zMECgcm0>	NYnKV5QyOjRiaB?=	NEPIZWlFVVOR	M1XEe4Rwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25?	NFXPSXMzPDB7M{m1Oi=>
SMMC-7721	NEK0S29HfW6ldHnvckBCe3OjeR?=	NVrKXmdzPTBxMUCwJI5O	MorwNlQhcA>?	MXzEUXNQ	M2TGcYRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25?	Mk\JNlQxQTN7NU[=
FaDu	MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHWbpJOOTBy4pEFcm0>	M3ywbVgwOTBxMUKgbC=>		NWfNbnln\Gm\|cHzhfYVlKGFic3nncolncWOjboSgZY5lKHC{b3zvcodm\CCJMj;NJIFzemW\|dDDheEA5KGGwZDCxNwKBjWhicH;zeEBz\WynYYPl	NHv3R5EzPDB{NkS4Ni=>
FaDu	MV7GeY5kfGmxbjDBd5NigQ>?	NVXScIpVOTBy4pEFcm0>	Ml\UNk81NzhxMUKgbC=>		NGPTW2pqdmS3Y3XkJJAzOVejZkGvR4lxOcLiZYjwdoV{e2mxbh?=	NIDaOmczPDB{NkS4Ni=>
PC-3	NX3qdFVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXYNE0yOCEQvF2=	MVKyOE81QC95MjDo		NXv6ZpJlcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M2LCUVI{QTlzMkG2
LNCaP	M2TPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVqwMVUh\|ryP	M4jNUVI1NzR6L{eyJIg>		MXHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MnW5NlM6QTF{MU[=
RWPE-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUmwMVIxKM7:TR?=	MnHiNlQwPDhxN{KgbC=>		M1\kVYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NYr5UGhYOjN7OUGyNVY>
Capan-1	MoTPSpVv[3Srb36gRZN{[Xl?	NWW5blJnOjVxNUCvNVAxKG6P	NU\je4Q3QC9{ND:0PEBp	MXTEUXNQ	NGPWfZVld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n	M3i2ZVI{QTJ{OEi2
L3.6pl	NXjSdZJMTnWwY4Tpc44hSXO\|YYm=	M2jZ[FI2NzVyL{GwNEBvVQ>?	M{LNU\|gwOjRxNEigbC=>	M4jJRWROW09?	Mkmw[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO\|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?=	Mn7jNlM6OjJ6OE[=
CFPAC-1	M3;zcGZ2dmO2aX;uJGF{e2G7	NEjTO3UzPS93MD:xNFAhdk1?	NHLHN5o5NzJ2L{S4JIg>	MXPEUXNQ	MUTkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p	NWfoXIFKOjN7MkK4PFY>
Capan-1	NEf2NJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrIWmh3OjVxNUCvNVAxKG6P	NXfXfnpIPDhiaB?=	M1LI[GROW09?	MWny[YR2[2W\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M4nVV\|I{QTJ{OEi2
L3.6pl	MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MornNlUwPTBxMUCwJI5O	NVTLVmJVPDhiaB?=	NYLnUopWTE2VTx?=	MmjGdoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NELGOWYzOzl{Mki4Oi=>
CFPAC-1	MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{noUlI2NzVyL{GwNEBvVQ>?	Ml;WOFghcA>?	MkDwSG1UVw>?	M3rJXJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NFzpTGgzOzl{Mki4Oi=>
Capan-1	MYPBdI9xfG:\|aYOgRZN{[Xl?	Mn64NlUwPTBxMUCwJI5O	M{DaO\|Q5KGh?	MVLEUXNQ	NEnldnJqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MmPsNlM6OjJ6OE[=
L3.6pl	M{\4XmFxd3C2b4Ppd{BCe3OjeR?=	NH3rbWwzPS93MD:xNFAhdk1?	M{TBflQ5KGh?	MkDOSG1UVw>?	NHv4XGhqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MoKyNlM6OjJ6OE[=
CFPAC-1	NIi3PJpCeG:ydH;zbZMhSXO\|YYm=	M4S5UlI2NzVyL{GwNEBvVQ>?	M3LiOVQ5KGh?	M1PBeGROW09?	M3\XXolv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NWTRPYZtOjN7MkK4PFY>
HN22	NYfUe2c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDDNE0zOCCwTR?=	NInoe2EzPC92ODDo	M4HhS2ROW09?	M{fWZolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI>	MkHoNlM5Pzd{M{W=
HSC4	M4W0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LSNVAuOjBibl2=	M{jDV\|I1NzR6IHi=	NI\wW\|lFVVOR	NV;Je4hXcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>?	NFvuZY0zOzh5N{KzOS=>
HN22	NHvtcoxCeG:ydH;zbZMhSXO\|YYm=	NF;1fngxNTJyIH7N	NIjiXYo1QCCq	M3f1TmROW09?	NWO4[2NOcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NXm4bIJXOjN6N{eyN\|U>
HSC4	NXK2RoJ3SXCxcITvd4l{KEG\|c3H5	NW[wWVFnOC1{MDDuUS=>	NUL4RWtRPDhiaB?=	NXrRbpl3TE2VTx?=	NGX0RoJqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NF7HU2IzOzh5N{KzOS=>
HN22	MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXj6fHRuOC1{MDDuUS=>	MYq0PEBp	NILF[lZFVVOR	MYXpcoR2[2W\|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC=	NYDUWVJ4OjN6N{eyN\|U>
HSC4	NWLPfmw2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXN[G4xNTJyIH7N	NUT1bVU6PDhiaB?=	MYfEUXNQ	MWXpcoR2[2W\|IFexJJBp[XOnIHPlcIwh[3mlbHWgZZJz\XO2wrC=	MUmyN\|g4PzJ\|NR?=
HN22	M3Pvb2Z2dmO2aX;uJGF{e2G7	NHrW[JcxNTJyIH7N	Mnv2OFghcA>?	NGDXZ\|dFVVOR	M1PYUZN2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=>	NY[3TlJpOjN6N{eyN\|U>
HSC4	NXzwcVhNTnWwY4Tpc44hSXO\|YYm=	NYjzfGNtOC1{MDDuUS=>	NU[2dY5{PDhiaB?=	MmjuSG1UVw>?	NHjifZR{fXCycnXzd4V{KFOyMTDlfJBz\XO\|aX;uxsA>	MorKNlM5Pzd{M{W=
Cal62	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLrOYpTUUN3ME2zN{DDuSB2IH7N	NGXxSmkzOzh{NEC2OC=>
Hth7	NVzzXZpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7ETWM2OD1zNTFCtUAzKG6P	MkLTNlM5OjRyNkS=
Hth83	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzCTWM2OD1\|NDFCtUA2KG6P	MmjoNlM5OjRyNkS=
C643	NHy4VIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDnWIlKSzVyPUexJOKyKDFyIH7N	NYizS3FyOjN6MkSwOlQ>
SW1736	MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjN[ldKSzVyPUO1JOKyKDhibl2=	MWqyN\|gzPDB4NB?=
T241	MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjZU4FKSzVyPU[1JOKyKDdibl2=	NU\uNFFwOjN6MkSwOlQ>
T351	NVz3U2ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHuTWM2OD13MDFCtUAyOCCwTR?=	MXyyN\|gzPDB4NB?=
BHP2-7	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPEWGxKSzVyPUO3JOKyKDZibl2=	MVuyN\|gzPDB4NB?=
T238	NXPFZWY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEGzN2NKSzVyPUGsOVAxKMLzIEKwNEBvVQ>?	NYPJcmJoOjN6MkSwOlQ>
HCT8	NHyx[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYK3NkBp	NXzwRYY4TE2VTx?=	MYPJR\|UxRTF{LkpihKnDueLCiUGuPUBvVQ>?	M2jx[FI{Ojl7M{i4
H630	NFzrboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M33tb\|czKGh?	M1PjUWROW09?	Mmm2TWM2OD1zMj605qCKyrIkgJmzMlEhdk1?	Mlj2NlMzQTl\|OEi=
cH630 5-FU-res	NVe0eFJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MUG3NkBp	NX3SUYJLTE2VTx?=	NVvN[\|lVUUN3ME2xOU426oDLwsJihKkyNjJibl2=	MmTsNlMzQTl\|OEi=
HCT116	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoDkO\|IhcA>?	NF\nVoxFVVOR	M3jCbWlEPTB;MUCuO-KBkcLz4pEJNk4zKG6P	MYKyN\|I6QTN6OB?=
HCT116 p53−/−	M4iwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVvHcXJ5PzJiaB?=	NIfaWVlFVVOR	NIKydYNKSzVyPUiuOwKBkcLz4pEJNU44KG6P	NE\NOo8zOzJ7OUO4PC=>
dHCT116 p21−/−	M176PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NITWN5Q4OiCq	NIrzb\|dFVVOR	MVHJR\|UxRTVwOfMAjeKy6oDLMT6zJI5O	M4LyOlI{Ojl7M{i4
HT29	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1XkXVczKGh?	M1zEZ2ROW09?	NVjnV\|dlUUN3ME2xOk4{6oDLwsJihKkzNjNibl2=	NF\ZU4ozOzJ7OUO4PC=>
LoVo	MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUHv[Gx3PzJiaB?=	M4SwS2ROW09?	NHPLVm9KSzVyPUWuNgKBkcLz4pEJNE43KG6P	NU\BToR6OjN{OUmzPFg>
RKO	NFHLdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2rweFczKGh?	NHHwNmlFVVOR	NGX5XJdKSzVyPUeuPgKBkcLz4pEJNk4zKG6P	NILGOnMzOzJ7OUO4PC=>
SW480	NGj3RXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYPESpp6PzJiaB?=	M3TB[GROW09?	MWXJR\|UxRTF5LkZihKnDueLCiUCuPEBvVQ>?	MoP1NlMzQTl\|OEi=
eSW620	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1faO\|czKGh?	MUXEUXNQ	NHf3U2lKSzVyPUmuNgKBkcLz4pEJNk4yKG6P	NEHmO3kzOzJ7OUO4PC=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 / EZH2; PubMed: 19279403 Cancer Biol Ther Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control. caspase-8 / cleaved caspase-8 / Sp1; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. c-Myc / IRF4; PubMed: 27738323 Oncotarget RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting. Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; PubMed: 28915627 Oncotarget Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1. RAD51 / BRCA1 / CHK1 / RPL13a; PubMed: 24244429 PLoS One CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells. H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; PubMed: 31071955 Int J Mol Sci Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.	19279403 27738323 28915627 24244429 31071955
Immunofluorescence	Synaptophysin / NACM; PubMed: 28915627 Oncotarget Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm. α-tubulin / Acetyl-α-tubulin; PubMed: 29983882 Oncotarget CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm. BiP; PubMed: 23544167 Transl Oncol Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. ATF4; PubMed: 23544167 Transl Oncol HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. IRE1α / S724-IRE1α; PubMed: 23544167 Transl Oncol Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.	28915627 29983882 23544167
Growth inhibition assay	Cell viability; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.	27738323

In vivo

In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. ^[2]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
Concentrations: 50 nM
Incubation Time: 48 hours
Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 10⁴ cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
(Only for Reference)

Animal Research:^[2]

- Collapse

Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (10⁷ cells) or A549 (5 × 10⁶ cells), H69 (2.5 × 10⁶ cells), BK-T (6.5 × 10⁶), H526 (10 × 10⁶), and RG1 (10 × 10⁶) cells
Dosages: 10 mg/kg, 20 mg/kg
Administration: Administered via i.p. injection
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	69 mg/mL (197.46 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+48% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Panobinostat (LBH589) SDF

Molecular Weight	349.43
Formula	C₂₁H₂₃N₃O₂
CAS No.	404950-80-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NVP-LBH589
Smiles	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=C([NH]1)C=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04341311	Not yet recruiting	Drug: Marizomib\|Drug: Panobinostat	Diffuse Intrinsic Pontine Glioma\|Pediatric Brainstem Glioma\|Pediatric Brainstem Gliosarcoma Recurrent\|Pediatric Cancer\|Pediatric Brain Tumor\|Diffuse Glioma	Dana-Farber Cancer Institute\|Celgene\|Secura Bio	May 2020	Phase 1
NCT03632317	Withdrawn	Drug: Panobinostat\|Drug: Everolimus	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	October 2019	Phase 2
NCT03982134	Withdrawn	Drug: PDR001\|Drug: Panobinostat	Melanoma\|Non Small Cell Lung Cancer	Muhammad Furqan\|Novartis Pharmaceuticals\|University of Iowa	September 2019	Phase 1
NCT04326764	Recruiting	Drug: Panobinostat	Acute Myeloid Leukaemia (AML)\|Myelodysplastic Syndromes (MDS)	Goethe University\|Jan J. Cornelissen (HOVON-SAKK)\|Sebastian Giebel (PALG)	July 24 2018	Phase 3
NCT03515915	Unknown status	--	Patients With Recurrent or Refractory Multiple Myeloma	University Hospital Montpellier\|Poitiers University Hospital	April 23 2018	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to reconstitute the compound for in vivo mice study?
Answer:
We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA for cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Panobinostat (LBH589)